Results 31 to 40 of about 24,516 (282)

Ischemia and reperfusion injury in kidney transplantation : relevant mechanisms in injury and repair [PDF]

, 2020
Ischemia and reperfusion injury (IRI) is a complex pathophysiological phenomenon, inevitable in kidney transplantation and one of the most important mechanisms for non- or delayed function immediately after transplantation.
Berger, Stefan P., Leuvenink, Henri G. D., Nieuwenhuijs-Moeke, Gertrude J., Pischke, Soren E., Ploeg, Rutger J., Pol, Robert A., Sanders, Jan Stephan F., Struys, Michel   +7 more
core   +2 more sources

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study

BMC Nephrology, 2019
Background There are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of patients with aHUS treated with ...
Jan Menne, Yahsou Delmas, Fadi Fakhouri, Christoph Licht, Åsa Lommelé, Enrico E. Minetti, François Provôt, Eric Rondeau, Neil S. Sheerin, Jimmy Wang, Laurent E. Weekers, Larry A. Greenbaum   +11 more
doaj   +1 more source

Prophylactic or Early Use of Eculizumab and Graft Survival in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome in the United States: Research Letter

Canadian Journal of Kidney Health and Disease, 2021
Introduction: Among kidney transplant recipients (KTRs) with end-stage kidney disease (ESKD) due to atypical hemolytic uremic syndrome (aHUS), recurrence is associated with poor allograft outcomes. We compared graft and patient survival of aHUS KTRs with
Richard A. Plasse, Stephen W. Olson, Christina M. Yuan, Lawrence Y. Agodoa, Kevin C. Abbott, Robert Nee   +5 more
doaj   +1 more source

Meningococcemia in a vaccinated child receiving eculizumab and review of the literature

The Turkish Journal of Pediatrics, 2023
Background. Atypical hemolytic uremic syndrome (aHUS) is a rare and severe disease characterized by uncontrolled activation and dysregulation of the alternative complement pathway and development of thrombotic microangiopathy. Eculizumab, which is
Diana Üçkardeş, Nilüfer Göknar, Nurhan Kasap, Emre Keleşoğlu, Mustafa Arga, Cengiz Candan   +5 more
doaj   +1 more source

How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome [PDF]

, 2014
Thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uraemic syndrome (aHUS) are acute, rare life-threatening thrombotic microangiopathies that require rapid diagnosis and treatment.
Goodship, T, Scully, M
core   +1 more source

Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre

BMC Nephrology, 2021
Background Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA). Methods This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the
Maximilien Grall, Florence Daviet, Noémie Jourde Chiche, François Provot, Claire Presne, Jean-Philippe Coindre, Claire Pouteil-Noble, Alexandre Karras, Dominique Guerrot, Arnaud François, Ygal Benhamou, Agnès Veyradier, Véronique Frémeaux-Bacchi, Paul Coppo, Steven Grangé   +14 more
doaj   +1 more source

Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice [PDF]

, 2019
Atypical hemolytic uremic syndrome (aHUS) is frequently associated in humans with loss-of-function mutations in complement-regulating proteins or gain-of-function mutations in complement-activating proteins.
Atkinson, John P, Barlow, Paul N, Cook, H. T, Cooke, Katie, Denton, Harriet, Kavanagh, David, Liszewski, M. K, Marchbank, Kevin J, Pappworth, Isabel Y, Pickering, Matthew C, Smith-Jackson, Kate, Yang, Yi   +11 more
core   +3 more sources

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

Journal of Comparative Effectiveness Research, 2023
Aim: Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Ravulizumab requires less frequent infusions than eculizumab, which may reduce treatment burden. This study investigated
Teri J Mauch, Michael R. Chladek, S. Cataland, Shruti Chaturvedi, B. Dixon, Katherine Garlo, C. Gasteyger, A. Java, Jorge P. Leguizamo, L. Lloyd-Price, T. Pham, T. Symonds, I. Tomazos, Yan Wang   +13 more
semanticscholar   +1 more source

Long‐term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real‐world setting

European Journal of Haematology, 2023
Describe the real‐world clinical profile of eculizumab‐treated patients by characterizing their short‐ and long‐term clinical and laboratory outcomes.
Katharina Versmold, F. Alashkar, Carina Raiser, R. Ofori-Asenso, T. Xu, Yutong Liu, P. Katz, A. Shang, A. Röth   +8 more
semanticscholar   +1 more source

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis

Frontiers in Medicine, 2023
Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by genetic abnormalities, infections, autoimmune diseases, drugs, and malignancies.
Sanober Sadiq, Anatoly Urisman, Onur Cil
doaj   +1 more source